All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubLymphoma HubMDS HubMPN HubMultiple Myeloma

What is the latest update on biomarkers for assessing GvHD?

During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Carrie L. Kitko, Vanderbilt University Medical Center, Nashville, US. We asked, What is the latest update on biomarkers for assessing GvHD?

What is the latest update on biomarkers for assessing GvHD?

Kitko begins by explaining how treatment response at Day 28 is used as a surrogate marker for long-term outcomes in clinical trials, despite limited accuracy. Kitko then discusses the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm, which can be used to estimate a patient's probability of 6-month nonrelapse mortality. Finally, Kitko talks about potential new biomarkers that were discussed at the Tandem Meetings.

Share: